LCAR1901

**LCAR1901** is an investigational dual-target anti-CD19 and anti-BCMA chimeric antigen receptor gene-therapy product administered as a one-time intravenous injection. It is being evaluated in exploratory, open-label, dose-escalation clinical studies sponsored by The First Affiliated Hospital of USTC for refractory autoimmune diseases and relapsed and refractory immune thrombocytopenia. The intended mechanism is depletion of CD19-positive B cells and BCMA-positive plasma cells, aiming to reset pathogenic humoral immunity and reduce autoantibody-producing cell populations. ([clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07121777))

Other names

Anti-CD19/BCMA CAR gene therapyAnti-CD19/BCMA CAR gene vectorAnti-CD19/BCMA CAR gene vector injection